Association of Urinary Laminin G-Like 3 and Free K Light Chains with Disease Activity and Histological Injury in IgA Nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 7, 2013, Pages 1115-1125

  Rocchetti, Maria Teresa ^a,b   Papale, Massimo ^a,b   D'Apollo, Anna Maria ^a   Suriano, Ida Valentina ^a   Di Palma, Anna Maria ^b   Vocino, Grazia ^a   Montemurno, Eustacchio ^b   Varraso, Leonarda ^a   Grandaliano, Giuseppe ^a   Di Paolo, Salvatore ^c   Gesualdo, Loreto ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Hospital Dimiccoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN LIGHT CHAIN; LAMININ; LAMININ G LIKE 3; PERLECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GLOMERULONEPHRITIS, IGA; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOHISTOCHEMISTRY; LAMININ; LINEAR MODELS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84879814877     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05950612     Document Type: Article

References (49)

1. Berger J: IgA glomerular deposits in renal disease. Transplant Proc 1: 939-944, 1969.
2. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088-2097, 2005.
3. Barratt J, Feehally J: Primary IgA nephropathy: New insights into pathogenesis. Semin Nephrol 31: 349-360, 2011.
4. Julian BA, Wittke S, Haubitz M, Zürbig P, Schiffer E, McGuire BM, Wyatt RJ, Novak J: Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol 25: 467-476, 2007.
5. Obara T, Mizoguchi S, Shimozuru Y, Sato T, Hotta O: The complex of immunoglobulin A and uromodulin as a diagnostic marker for immunoglobulinA nephropathy. Clin ExpNephrol 16: 713-721, 2012.
6. Harada K, Akai Y, Kurumatani N, Iwano M, Saito Y: Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: An 8-year follow-up study. Nephron 92: 824-826, 2002.
7. Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP: The ratio of epidermal growth factor to monocyte chemotactic peptide- 1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73: 327-333, 2008.
8. Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, Economidou D, Leontsini M, Memmos D: Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton) 14: 613-620, 2009.
9. Brabcova I, Tesar V, Honsova E, Lodererova A, Novotna E, Maixnerova D, Merta M, Bürgelova M, Hribova P, Skibova J, Zadrazil J, Maly J, Viklicky O: Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrol Dial Transplant 26: 573-579, 2011.
10. Silva GE, Costa RS, Ravinal RC, Ramalho LZ, Dos Reis MA, Coimbra TM, Dantas M: NF-kB expression in IgA nephropathy outcome. Dis Markers 31: 9-15, 2011.
11. Tan Y, Zhang JJ, Liu G, Zhang H, Zhao MH: The level of urinary secretory immunoglobulin A (sIgA) of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Clin Exp Immunol 156: 111-116, 2009.
12. Gao J, Cui J, Wang Y, Dong Z, Tian Y, Xu Y: Identification of potential predictors for subtype IgA nephropathy through analyses of blood biochemical indicators. Clin Chim Acta 412: 441-445, 2011.
13. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C: The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 6: 2384-2388, 2011.
14. Thongboonkerd V: Current status of renal and urinary proteomics: Ready for routine clinical application? Nephrol Dial Transplant 25: 11-16, 2010.
15. Arthur JM, Klein JB: Proteomics in CKD. Adv Chronic Kidney Dis 17: 453-454, 2010.
16. Rocchetti MT, Papale M, Gesualdo L: Urine protein profiling in immunoglobulin A nephropathy. US Nephrology 5: 56-63, 2010.
17. Papale M, Di Paolo S, Magistroni R, Lamacchia O, Di Palma AM, De Mattia A, Rocchetti MT, Furci L, Pasquali S, De Cosmo S, Cignarelli M, Gesualdo L: Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes Care 33: 2409-2415, 2010.
18. Out HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R: Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 30: 638-643, 2007.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187, 2007.
20. Rocchetti MT, Tamma G, Lasorsa D, Suriano IV, D'Apollo A, Papale M, Mastrofrancesco L, Grandaliano G, Svelto M, Valenti G, Gesualdo L, Di Paolo S: Altered urinary excretion of aquaporin 2 in IgA nephropathy. Eur J Endocrinol 165: 657-664, 2011.
21. Papale M, Pedicillo MC, Thatcher BJ, Di Paolo S, Lo Muzio L, Bufo P, Rocchetti MT, Centra M, Ranieri E, Gesualdo L: Urine profiling by SELDI-TOF/MS: Monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci 856: 205-213, 2007.
22. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545, 2009.
23. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA NephropathyNetwork and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009.
24. Rocchetti MT, Centra M, Papale M, Bortone G, Palermo C, Centonze D, Ranieri E, Di Paolo S, Gesualdo L: Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 8: 206-216, 2008.
25. Morales JV, Weber R, Wagner MB, Barros EJC: Is morning urinary protein/creatinine ratio a reliable estimator of 24-hour proteinuria in patients with glomerulonephritis and different levels of renal function? J Nephrol 17: 666-672, 2004.
26. Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, Zhu SN, Liu G, Zou WZ, Zhang H, Wang HY: Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: Validation of the oxford classification. Clin J AmSoc Nephrol 6: 2175-2184, 2011.
27. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H: Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67: 2313-2320, 2005.
28. Wu J, Wang N, Wang J, Xie Y, Li Y, Liang T, Wang J, Yin Z, He K, Chen X: Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom 24: 1971-1978, 2010.
29. Moon PG, Lee JE, You S, Kim TK, Cho JH, Kim IS, Kwon TH, Kim CD, Park SH, Hwang D, Kim YL, Baek MC: Proteomic analysis of urinary exosomes frompatients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 11: 2459-2475, 2011.
30. Solling K: Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 157: 1-83, 1981.
31. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D: Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney Int 16: 251-270, 1979.
32. Christensen EI, Birn H: Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 280: F562-F573, 2001.
33. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1684-1690, 2008.
34. Ronco P, Plaisier E, Mougenot B, Aucouturier P: Immunoglobulin light (heavy)-chain deposition disease: Frommolecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1: 1342-1350, 2006.
35. Mastroianni-Kirsztajn G, Nishida SK, Pereira AB: Are urinary levels of free light chains of immunoglobulins useful markers for differentiating between sistemic lupus erythematosus and infection? Nephron Clin Pract 110: c258-c263, 2008.
36. Tsai CY, Wu TH, Sun KH, Lin WM, Yu CL: Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann Rheum Dis 51: 168-172, 1992.
37. Cohen G, Hörl WH: Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial 22: 369-372, 2009.
38. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA: Free immunoglobulin light chains: A novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 29: 170-174, 2008.
39. Wang PX, Sanders PW: Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 18: 1239-1245, 2007.
40. Keeling J, Herrera GA: The mesangium as a target for glomerulopathic light and heavy chains: Pathogenic considerations in light and heavy chain mediated glomerular damage. In: The Kidney in Plasma Cell Dyscrasias, edited by Herrera GA, Basel, Switzerland, Karger, 2007, pp 116-134.
41. Kallunki P, Eddy RL, Byers MG, KestiläM, Shows TB, Tryggvason K: Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 1p36.1-p35 and identification of a BamHI restriction fragment length polymorphism. Genomics 11: 389-396, 1991.
42. Björnson A, Moses J, Ingemansson A, Haraldsson B, Sörensson J: Primary human glomerular endothelial cells produce proteoglycans, and puromycin affects their posttranslational modification. Am J Physiol Renal Physiol 288: F748-F756, 2005.
43. Bix G, Iozzo RV: Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis. Microsc Res Tech 71: 339-348, 2008.
44. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV: Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278: 4238-4249, 2003.
45. Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS, Iozzo RV: BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280: 7080-7087, 2005.
46. Ebefors K, Granqvist A, Ingelsten M, Mölne J, Haraldsson B, Nyström J: Role of glomerular proteoglycans in IgA nephropathy. PLoS One 6: e18575, 2011.
47. Soulez M, Sirois I, Brassard N, Raymond MA, Nicodeme F, Noiseux N, Durocher Y, Pshezhetsky AV, Hébert MJ: Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells 28: 810-820, 2010.
48. Ranieri E, Gesualdo L, Petrarulo F, Schena FP: Urinary IL-6/EGF ratio: A useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50: 1990-2001, 1996.
49. Saini MG, Pinteaux E, Lee B, Bix GJ: Oxygen-glucose deprivation and interleukin-1a trigger the release of perlecan LG3 by cells of neurovascular unit. J Neurochem 119: 760-771, 2011